{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:39Z","timestamp":1788401739213,"version":"build-2803163510"},"reference-count":30,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>DNA-targeting indolinobenzodiazepine dimer (IGN) payloads are used in several clinical-stage antibody\u2013drug conjugates. IGN drugs alkylate DNA through the single imine moiety present in the dimer in contrast to the pyrrolobenzodiazepine dimer drugs, such as talirine and tesirine, which contain two imine moieties per dimer and cross-link DNA. This study explored the mechanism of binding of IGN to DNA in cells and to synthetic duplex and hairpin oligonucleotides. New, highly sensitive IGN\u2013DNA binding enzyme-linked immunosorbent assay methods were developed using biotinylated IGN analogues (monoimine, diimine, and diamine IGNs) and digoxigenin-labeled duplex oligonucleotides, which allowed the measurement of drug\u2013DNA adducts in viable cells at concentrations below IC50. Furthermore, the release of free drug from the IGN\u2013DNA adduct upon treatment with nuclease ex vivo was tested under physiological conditions. The monoimine IGN drug formed a highly stable adduct with DNA in cells, with stability similar to that of the diimine drug analogue. Both monoimine and diimine IGN\u2013DNA adducts released free drugs upon DNA cleavage by nuclease at 37 \u00b0C, although more free drug was released from the monoimine compared to the diimine adduct, which presumably was partly cross-linked. The strong binding of the monoimine IGN drug to duplex DNA results from both the noncovalent IGN\u2013DNA interaction and the covalent bond formation between the 2-amino group of a guanine residue and the imine moiety in IGN.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.9b00675","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:08:11Z","timestamp":1574165291000},"page":"50-58","source":"Crossref","is-referenced-by-count":12,"title":["Antibody\u2013Drug\nConjugates with Indolinobenzodiazepine\nDimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer\nCatabolites in Target Cancer Cells"],"prefix":"10.1021","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1537-6209","authenticated-orcid":true,"given":"Rajeeva","family":"Singh","sequence":"first","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Reid","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Harris","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulin L.","family":"Salomon","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-3319","authenticated-orcid":true,"given":"Michael L.","family":"Miller","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi V. J.","family":"Chari","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Keating","sequence":"additional","affiliation":[{"name":"ImmunoGen, Inc. , 830 Winter Street , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"2026090221481390600_cit1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-Drug Conjugates for Cancer Treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"2026090221481390600_cit2","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1093\/annonc\/mdx541","article-title":"The antibody-drug\nconjugate target landscape across a broad range of tumour types","volume":"28","author":"Moek","year":"2017","journal-title":"Ann. Oncol."},{"key":"2026090221481390600_cit3","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-Drug\nConjugates: Future Directions in Clinical\nand Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026090221481390600_cit4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From Anthramycin\nto Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates\n(ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew. Chem., Int. Ed."},{"key":"2026090221481390600_cit5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and Synthesis of Tesirine, a Clinical Antibody-Drug\nConjugate Pyrrolobenzodiazepine Dimer Payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"2026090221481390600_cit6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A New\nClass of Antibody-Drug Conjugates with Potent\nDNA Alkylating Activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2026090221481390600_cit7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","article-title":"A DNA-Interacting\nPayload Designed to Eliminate Cross-Linking\nImproves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)","volume":"17","author":"Miller","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026090221481390600_cit8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting\nantibody-drug conjugate, IMGN632,\ndesigned to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"2026090221481390600_cit9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544:\na CD22-targeted immunoconjugate of calicheamicin for the treatment\nof B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"2026090221481390600_cit10","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized\nanti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse\nepithelial cancers: preclinical studies in human cancer xenograft\nmodels and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2026090221481390600_cit11","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a,\nA Novel HER2-Targeting\nADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising\nAntitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2026090221481390600_cit12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin\nversus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2026090221481390600_cit13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase\n1 trial of vadastuximab talirine as\nmonotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"2026090221481390600_cit14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and Safety\nof Rovalpituzumab Tesirine in Third-Line\nand Beyond Patients with DLL3-Expressing, Relapsed\/Refractory Small\nCell Lung Cancer: Results From the Phase II TRINITY Study","author":"Morgensztern","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026090221481390600_cit15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12254-018-0441-x","article-title":"ASCO 2018: highlights\nin HER2-positive metastatic breast\ncancer","volume":"11","author":"Bartsch","year":"2018","journal-title":"Mag. Eur. Med. Oncol."},{"key":"2026090221481390600_cit16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2013.07.006","article-title":"From old alkylating\nagents to new\nminor groove binders","volume":"89","author":"Puyo","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026090221481390600_cit17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.6494915","article-title":"Reaction of\nthe antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct\nwith DNA sequence specificity","volume":"226","author":"Hurley","year":"1984","journal-title":"Science"},{"key":"2026090221481390600_cit18","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1021\/bi00185a043","article-title":"Mapping of DNA alkylation\nsites induced\nby adozelesin and bizelesin in human cells by ligation-mediated polymerase\nchain reaction","volume":"33","author":"Lee","year":"1994","journal-title":"Biochemistry"},{"key":"2026090221481390600_cit19","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1073\/pnas.92.9.3642","article-title":"CC-1065 and the duocarmycins: unraveling the keys to\na new class of naturally derived DNA alkylating agents","volume":"92","author":"Boger","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026090221481390600_cit20","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.1073\/pnas.83.18.6702","article-title":"Reaction of DNA with\nchemically or enzymatically activated mitomycin C: isolation and structure\nof the major covalent adduct","volume":"83","author":"Tomasz","year":"1986","journal-title":"Proc. Natl. Acad.\nSci. U.S.A."},{"key":"2026090221481390600_cit21","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1093\/nar\/gkr122","article-title":"Effect\nof base sequence on the DNA\ncross-linking properties of pyrrolobenzodiazepine (PBD) dimers","volume":"39","author":"Rahman","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"2026090221481390600_cit22","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/bi102017e","article-title":"Nuclear\nmagnetic resonance solution structures of inter-\nand intrastrand adducts of DNA cross-linker SJG-136","volume":"50","author":"Hopton","year":"2011","journal-title":"Biochemistry"},{"key":"2026090221481390600_cit23","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1093\/nar\/gki639","article-title":"The\nXPF-ERCC1 endonuclease and homologous recombination\ncontribute to the repair of minor groove DNA interstrand crosslinks\nin mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine\ndimer SJG-136","volume":"33","author":"Clingen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"2026090221481390600_cit24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody Drug Conjugates Differentiate Uptake\nand DNA Alkylation of Pyrrolobenzodiazepines in Tumors from Organs\nof Xenograft Mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"2026090221481390600_cit25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1535-7163.mct-17-0697","article-title":"Intratumoral Payload\nConcentration Correlates\nwith the Activity of Antibody-Drug Conjugates","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026090221481390600_cit26","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1021\/acs.molpharmaceut.5b00028","article-title":"Sensitive ELISA Method\nfor the Measurement of Catabolites of Antibody-Drug\nConjugates (ADCs) in Target Cancer Cells","volume":"12","author":"Salomon","year":"2015","journal-title":"Mol.\nPharm."},{"key":"2026090221481390600_cit27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2018.12.014","article-title":"An LC\/MS\nbased method to quantify DNA adduct in tumor\nand organ tissues","volume":"568","author":"Li","year":"2019","journal-title":"Anal. Biochem."},{"key":"2026090221481390600_cit28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1042\/bj20021847","article-title":"Cleavage of fragments\ncontaining\nDNA mismatches by enzymic and chemical probes","volume":"371","author":"Brown","year":"2003","journal-title":"Biochem. J."},{"key":"2026090221481390600_cit29","doi-asserted-by":"publisher","first-page":"19376","DOI":"10.1021\/ja205395r","article-title":"Observation\nof a single-stranded DNA\/pyrrolobenzodiazepine adduct","volume":"133","author":"Rahman","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"2026090221481390600_cit30","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical\npharmacology and mechanism of action of SG3199, the\npyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug\nconjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.9b00675","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/17\/1\/50\/67091387\/acs.molpharmaceut.9b00675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/17\/1\/50\/67091387\/acs.molpharmaceut.9b00675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:56Z","timestamp":1788400196000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/17\/1\/50\/507446\/Antibody-Drug-Conjugates-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,19]]},"published-print":{"date-parts":[[2020,1,6]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00675","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]}}}